Nyxoah (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces the end of the stabilization period in the framework of its initial public offering of new shares with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “NYXH” (the “Offering“).
Within the framework of the Offering, Belfius Bank NV/SA (“Belfius“), acting on behalf of the Underwriters (as defined below), was appointed by the Company as stabilization manager (the “Stabilization Manager“), and was granted (and subscribed for) an over-allotment option (in the form of a warrant) to subscribe for 650,250 additional new shares at the final offering price of €17.00 per share in order to cover any over-allotments or short positions in relation to the Offering (the “Over-allotment Option“). The Over-allotment Option was exercisable for a period of 30 calendar days following the first day on which the shares were admitted to trading on the regulated market of Euronext Brussels (i.e., 18 September 2020).
The Over-allotment Option was fully exercised by the Stabilization Manager, on behalf of the Underwriters, and 650,250 additional new shares will be issued on Tuesday 29 September 2020, so that the Company raised an additional €11.05 million in gross proceeds in the context of the Offering.
As a result, the total number of new shares issued by the Company in the context of the Offering amounts to 4,985,250 new shares, and the total gross proceeds raised in the context of the Offering amounts to €84.75 million ($100 million).
Following the full exercise of the full Over-allotment Option, the Company has 22,074,109 outstanding shares following the capital increase taking place on Tuesday 29 September 2020.
The stabilization period commenced on 18 September 2020 and ended on 24 September 2020.
For an overview of the dilution resulting from the Offering, reference is made to Section 11 “Significant Shareholders” of the Prospectus prepared by the Company in connection with the Offering and available on the Company’s website (www.nyxoah.com).
Underwriters involved in the Offering
Bank Degroof Petercam NV/SA and Belfius Bank NV/SA acted as Joint Global Coordinators and Joint Bookrunners in the Offering (together, the “Underwriters“).
– ENDS –
For further information, please contact:
Nyxoah
Rémi Renard, VP Therapy Development and Education
remi.renard@nyxoah.com
+32 472 12 64 40
For media enquiries, please contact:
Consilium Strategic Communications
Amber Fennell, Ashley Tapp, Lindsey Neville, Taiana De Ruyck Soares
Nyxoah@consilium-comms.com
+44 (0)20 3709 5700
About Nyxoah
Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a CE-validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.
Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit www.nyxoah.com.